공시 • Mar 10
SR biotek Inc., Annual General Meeting, Mar 24, 2026 SR biotek Inc., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South Korea New Risk • Nov 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$19.5m). New Risk • Aug 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩40.4b market cap, or US$29.2m). New Risk • May 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$29.4m). 공시 • Feb 20
SR biotek Inc., Annual General Meeting, Mar 27, 2025 SR biotek Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South Korea New Risk • Jan 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩36.8b market cap, or US$25.1m). 공시 • Jun 18
SR biotek Inc. announced that it has received KRW 1.65 billion in funding from Craver Corporation and other investors On June 17, 2024, SR biotek Inc. closed the transaction. 공시 • Nov 22
SR biotek Inc. announced that it expects to receive KRW 443.8467 million in funding SR biotek Inc. announced a private placement of 134,499 common shares at an issue price of KRW 3,300 per share for gross proceeds of KRW 443,846,700 on November 21, 2022. The transaction will include participation from Craver Corporation Co., Ltd. for 116,399 shares, individual investors, Byeongho Song for 15,768 shares and Hong-gun Yoon for 2,332 shares. The common shares will have a lock-up period of one year. The transaction has been approved by board of directors of the company. The expected date of payment is December 6, 2022. 공시 • Mar 18
SR biotek Inc., Annual General Meeting, Mar 31, 2021 SR biotek Inc., Annual General Meeting, Mar 31, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Feb 25
New 90-day low: ₩6,010 The company is down 24% from its price of ₩7,870 on 27 November 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period. Is New 90 Day High Low • Feb 04
New 90-day high: ₩9,420 The company is up 52% from its price of ₩6,200 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 16% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: ₩8,400 The company is up 6.0% from its price of ₩7,890 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period. Is New 90 Day High Low • Nov 05
New 90-day low: ₩5,900 The company is down 26% from its price of ₩8,000 on 07 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is flat over the same period. 